Objective： To analyze the clinical infusion effect of frozen-thawed-deglycerolized red blood cells (FTD-RBCs) and provide solutions for situations such as blood supply shortages. Methods： In this retrospective study, 280 patients receiving FTD-RBCs and 280 patients receiving suspended red blood cells (SRBCs) in our hospital from December 2019 to June 2022 were included. We collected the course records and laboratory test results, including basic information, total amount of transfusion, as well as RBC count, hemoglobin concentration (HGB) and hematocrit（HCT）24 h before and after the transfusion, and whether there were adverse blood transfusion reactions. Clinical efficacy analysis of FTD-RBCs was conducted by Mann-Whitney U test and Kruskal-Wallis H test. Results: In the 280 patients of our study, RBC count, HGB and HCT increased significantly after transfusion of FTD-RBCs (P＜0.05). For transfusion of one FTD-RBC unit, the median of differences in RBC count, HGB and HCT before and after transfusion were 0.310*1012/L, 9.735 g/L and 2.800%, respectively. The increments of the three indicators in the FTD-RBC group were all lower than those in the SRBC group, but the differences were not statistically significant (P > 0.05). None of the patients in this study had adverse transfusion reactions after transfusion of FTD-RBCs. In addition, we found that the efficacy of FTD-RBCs transfusion was associated with sex, age, body weight, disease type and blood type of the patient (P＜0.05). Conclusion: The infusion of FTD-RBCs for clinical patients is safe and effective, and it is an effective blood supply supplement in situations of blood shortage such as public health events. Key words：Frozen-thawed-deglycerolized RBCs, RBC count, HGB, HCT
Wang et al. (Tue,) studied this question.